Pharmaceutical Industry Information Portal

HomeNewsletter

Newsletter

FDA Authorizes Use of Oral Antiviral Molnupiravir for Mild to Moderate COVID-19

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the U.S. Food and Drug Administration (FDA) has...

Russian Ministry of Health registered Mir-19 anti-coronavirus drug

The Russian Ministry of Health registered the Mir-19 coronavirus pharmaceuticals developed by the Russian Federal Medical-Biological Agency (FMBA), the agency’s press service said. The press...

Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has authorized the emergency use of PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets)...

Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced enrollment of the first participants in...

The launch of R&D centre at BratskChemSyntez LLC

The R&D centre is tasked to optimise its substance manufacturing process and develop new unique molecules. The complex has modern and high-precision equipment that allows...

EMA evaluating data on booster dose of COVID-19 vaccine Comirnaty

EMA has started evaluating an application for the use of a booster dose of Comirnaty to be given 6 months after the second dose...
spot_img

Expert Articles

spot_img